{"name":"Mitsubishi Tanabe Pharma","slug":"mitsubishi-tanabe","ticker":"4508.T","exchange":"TSE","domain":"mt-pharma.co.jp","description":"Tanabe Pharma Corporation  is a Japanese pharmaceuticals company from Osaka, a subsidiary of Mitsubishi Chemical Holdings Corporation. Mitsubishi Pharma Corporation  was formed in 2001 from the merger of Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation. On October 1, 2007, Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma to form Mitsubishi Tanabe Pharma.","hq":"Osaka, Japan","founded":1962,"employees":"~75,000","ceo":"Hiroaki Ueno","sector":"Autoimmune / CNS / Rare Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153400000000","metrics":{"revenue":4200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Radicava patent cliff ($1.2B at risk)","drug":"Radicava","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-08","type":"regulatory","headline":"Mitsubishi Tanabe Pharma's Radicava receives FDA approval for ALS treatment","summary":"The FDA approved Radicava for the treatment of amyotrophic lateral sclerosis (ALS) in the US.","drugName":"Radicava","sentiment":"positive"},{"date":"2022-05-10","type":"earnings","headline":"Mitsubishi Tanabe Pharma reports Q1 2022 earnings","summary":"The company reported a net income of ¥5.4 billion for the quarter.","drugName":"","sentiment":"neutral"},{"date":"2021-03-01","type":"deal","headline":"Mitsubishi Tanabe Pharma partners with Biogen for multiple sclerosis treatment","summary":"The company partnered with Biogen to develop a new treatment for multiple sclerosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPVFYzYzh2eTdKcUl6clJyc21kLUlJeXN2N1MxZGNFNGlVakZua3pSeGFUTjczTlhCNHl3V1drRnExT240cTVxd1JrRHJnOHdzMjdzamFJQUhmaDd1YjRNbjJReHNxa0pCclgycVJwWVFUd3dqeWJHSlN2R1B1OXhRdzdkTGJUOG5BU0R2VU5WSkxhMVVJMGFkaHlXUTA2aDg?oc=5","date":"2025-01-07","type":"pipeline","source":"The Pharma Letter","summary":"Dewpoint’s big year ends with a bang and even bigger hopes for 2025 - The Pharma Letter","headline":"Dewpoint’s big year ends with a bang and even bigger hopes for 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxObTM4SlpiZlE0UTRuZjBZeTNyQzhlTVE4anNQemc3LTRHRTRsUVFvMm8wU0xYV3Z1ZHFUcndmbEctS3NRUDA5eDd0UVZnRlZiejVwZ3dGeE1zVE00aGhrblk3d09RRHNweXoyWl9WdFdtVWdxclpNM2ozQVZZS2FDdWNZQktVbnRpUXNEZ3A3djhCU09jeDE0SXFZc21sSUE1Q3RTb0t0VkVWVkpnUUhz?oc=5","date":"2015-09-16","type":"deal","source":"Reuters","summary":"Amgen to buy Dezima Pharma for $300 million in cash - Reuters","headline":"Amgen to buy Dezima Pharma for $300 million in cash","sentiment":"neutral"}],"patents":[{"drugName":"Radicava","drugSlug":"edaravone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co.","Ono Pharmaceutical"],"therapeuticFocus":["Autoimmune","CNS","Rare Disease"],"financials":null,"yahoo":null}